Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1297

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 11
Chunk 1297
---
    (1)
    Unless
    otherwise denoted, the address of each noted person is 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131.

    (2)
    Includes
    both founders shares and shares subject to options granted under our 2022 Omnibus Plan that are exercisable as of the Beneficial
    Ownership Date or within 60 days of the Beneficial Ownership Date held as follows: Mr. Aminov, 2,561,200 shares and Ms. Yanez,
    136,111 shares, , Dr. Del Guidice, 25,000 shares, Dr. Shekhat, 41,666 shares, Mr. MacPherson, 25,000 shares, and all current
    officers and directors as a group, 2,256,777 shares. Excludes shares subject to options granted under our 2022 Omnibus Plan that are
    not exercisable within 60 days of the Beneficial Ownership Date.

    (3)
    Includes
    (i) 10,000 shares held directly by Mr. McNulty, (ii) 2,540,270 shares held by the Bay Shore Trust, (iii) 779,047 shares held by the
    Celeste J Williams Lifetime QTIP Trust, (iv) 1,000,000 shares issuable pursuant to warrants held by the Bay Shore Trust that are
    immediately exercisable, and (v) 700,000 shares issuable pursuant to warrants held by MIRALOGX LLC, that are immediately exercisable.
    As trustee of the Bay Shore Trust and the Celeste J Williams Lifetime QTIP Trust, Mr. McNulty has sole voting and dispositive power
    over the shares held by each trust, and, as a result is deemed to have beneficial ownership (as determined under Section 13(d) of
    the Exchange Act) of the securities held by the trusts. The address for MIRALOGX LLC and the Bay Shore Trust is 900 West Platt Street,
    Suite 200, Tampa, Florida, 33606.

DELINQUENT
SECTION 16(A) REPORTS

Section
16(a) of the Exchange Act requires directors and executive officers, and persons who own more than 10% of the Company’s common
stock, to report to the SEC their initial ownership of the Company’s common stock and any subsequent changes in that ownership.
Specific due dates for